Skip to main content
SpringerLink
Log in

Systemic Therapy of Advanced Breast Cancer

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Many cytotoxic agents have demonstrated activity in advanced breast cancer, the more active agents being cyclophosphamide and the anthracyclines doxorubicin and epirubicin. Combinations of drugs are generally superior to single agents in terms of response rate, duration of response and survival.

The treatment of advanced breast cancer can be continued either until treatment failure, or for a limited time from either initiation of therapy or from the observation of complete response. Although these are issues of significant concern, data from randomised trials are limited, and so the question of optimal treatment duration remains open.

Randomised trials comparing regimens that differ by a dose intensity factor of less than 2 have failed to demonstrate significant differences in efficacy between the dose levels. With higher doses, as applied in combination with colony-stimulating factors and bone marrow transplantation, response rates seem to increase, but whether this translates into improved survival has not yet been answered by the results of randomised trials.

Approximately 30% of patients respond to endocrine therapy. From the results of randomised trials, which have compared the efficacies and toxicities of different endocrine modalities including combined endocrine therapy, single-agent tamoxifen is generally considered as the preferred first-line treatment, leaving progestins and aromatase inhibitors as alternatives for second-line endocrine therapy in responders.

In the majority of trials, chemotherapy combined with endocrine therapy has given improved response rates compared with chemotherapy alone, but the differences have not generally been translated into prolonged survival with combined modalities. This gives rise to the question of the optimal sequence of chemotherapy and endocrine therapy, a subject needing further evaluation in future trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ahmann DL, Bisel HF, Eagan RT, et al. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemotherapy Reports 58: 877–882, 1974

    CAS  Google Scholar 

  • Aisner J, Weinberg V, Perloff M, et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast. A CALGB study. Journal of Clinical Oncology 5: 1523–1533, 1987

    CAS  Google Scholar 

  • Andersson M, Mouridsen HT. Mitoxantrone as single chemotherapeutic agent for advanced breast cancer: the phase II trial experience. In Mouridsen HT, Arlin ZA (Eds) The role of mitoxantrone in malignant diseases, pp. 31–47, PharmaLibri, Chicago, 1987

    Google Scholar 

  • Antman K, Gole RP. Advanced breast cancer: high dose chemotherapy and bone marrow autotransplants. Annals of Internal Medicine 108: 570–574, 1988

    PubMed  CAS  Google Scholar 

  • Australian and New Zealand Breast Cancer Trial Group. A randomised trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. Journal of Clinical Oncology 4: 186–193, 1986

    Google Scholar 

  • Bastholt L, Dalmark M, Gjedde S, et al. Epirubicin at four different dose levels in advanced breast cancer. An interim analyses of a randomized trial. Abstract A74. Proceedings of the 5th EORTC Breast Cancer Working Conference, Leuven, 1991

  • Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2: 162–165, 1896

    Article  Google Scholar 

  • Beex LVAM, Rose C, Sylvester R, et al. Continuous tamoxifen vsintermittent tamoxifen vs alternating tamoxifen and medroxyprogesterone acetate (MPA). First-line endocrine therapy for postmenopausal patients with advanced breast cancer. A phase III study (Trial 10863). Abstract 1.14. Proceedings of the 4th EORTC Breast Cancer Working Conference, London, 1987

  • Bennet JM, Muus HB, Doroshow JH, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide and fluorouracil with doxorubicin, cyclophosphamide and fluorouracil in the therapy of metastatic breast carcinoma. Journal of Clinical Oncology 6: 1611–1620, 1988

    Google Scholar 

  • Beretta G, Tabiadon D, Tedeschi L, et al. Frontline treatment with CMF variations for advanced breast carcinoma. A randomized study. Proceedings of the American Society of Clinical Oncologists 300: 77, 1986

    Google Scholar 

  • Bonneterre J, Coopens H, Mauriac L, et al. Aminoglutethimide in advanced breast cancer: clinical results of a French multicentre randomised trial comparing 500mg and 1 g/day. European Journal of Cancer and Clinical Oncology 21: 1153–1158, 1985

    Article  CAS  Google Scholar 

  • Brincker H, Rose C, von der Maase H, Dombernowsky P. A randomized study of CAF + TAM (tamoxifen) versus CMF + TAM in metastatic breast cancer. Proceedings of the American Society of Clinical Oncologists 3: 113, 1984

    Google Scholar 

  • Bruchowsky N, Rennie P, van Doorn E, et al. Pathological growth of androgen sensitive tissue resulting from latent actions of steroid hormones. Journal of Toxicology and Environmental Health 4: 391–408, 1978

    Article  Google Scholar 

  • Bruno M, Roldan E, Diaz B. Sequential vssimultaneous admin- istration of tamoxifen and medroxyprogesterone acetate in ad- vanced breast cancer. Abstract 261. Journal of Steroid Biochemistry 19: 87S, 1983

    Article  Google Scholar 

  • Buchanan RB, Blarney RW, Durrant KR, et al. A randomised comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. Journal of Clinical Oncology 4: 1326–1330, 1986

    PubMed  CAS  Google Scholar 

  • Bull JM, Tormey DC, Shou-Hua L, et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657, 1978

    Article  PubMed  CAS  Google Scholar 

  • Buyukunal E, Derman U, Serdengecti S, Berkarda B. A clinical trial of mitoxantrone (Novantrone) versus doxorubicin (Adriamycin) in combination chemotherapy for metastatic breast cancer. Chemioterapia 6: 377–379, 1987

    PubMed  CAS  Google Scholar 

  • Cáceres E, Valdivia S, López-Belió M, et al. Mitoxantrone, 5- fluorouracil and methotrexate versus cyclophosphamide, 5- fluorouracil and methotrexate in advanced breast cancer. Proceedings of the American Society of Clinical Oncologists 5: 76, 1986

    Google Scholar 

  • Canellos GP, Pocock SJ, Taylor SG, et al. Combination chemotherapy of metastic breast carcinoma: prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38: 1882–1886, 1976

    Article  PubMed  CAS  Google Scholar 

  • Cantwell B. Short course mitoxantrone versus continuous chemo- therapy in advanced breast cancer. Proceedings of the 2nd Nordic Novantrone Symposium, Oslo, 1988

  • Cantwell BMJ, Robinson A, Millward MJ, Lind MJ. Prolonged (14 days) oral etoposide with weekly infusions of low dose cisplatin for pretreated advanced breast cancer patients. British Journal of Cancer 64 (Suppl. 15): 24, 1991

    Google Scholar 

  • Carmo-Pereira J, Oliveira Costa F, Henriques E, et al. A comparison of two doses of adriamycin in the primary chemo- therapy of disseminated breast carcinoma. British Journal of Cancer 56: 471–473, 1987

    Article  PubMed  CAS  Google Scholar 

  • Carter SK. Integration of chemotherapy into combined modality treatment of solid tumors. VII. Adenocarcinoma of the breast. Cancer Treatment Reviews 3: 141–174, 1976

    Article  PubMed  CAS  Google Scholar 

  • Cavalli F, Beer M, Martz G, et al. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. British Medical Journal 286: 5–8, 1983

    Article  PubMed  CAS  Google Scholar 

  • Cavalli F, Goldhirsch A, Jungi F, et al. Randomised trial of low vshigh-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer: the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology 2: 414–419, 1984

    PubMed  CAS  Google Scholar 

  • i G, Cocconi G, Bisagni G, et al. Aminoglutethimide (AG) with and without hydrocortisone (HC) as a first-line endocrine therapy (ET) in metastatic breast carcinoma (M). A prospective randomized trial. Abstract 26/36. Third IST International Symposium. Biology and Therapy of Breast Cancer, Genoa, 25–27 September, 1989

  • Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. New England Journal of Medicine 317: 1490–1495, 1987

    Article  PubMed  CAS  Google Scholar 

  • Cocconi G, Bisague G, Bacchi M, et al. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology 9: 664–669, 1991

    PubMed  CAS  Google Scholar 

  • Cooper RG. Combination chemotherapy in hormone resistant breast cancer. Proceedings of the American Society of Clinical Oncologists 10: 15, 1969

    Google Scholar 

  • Cowan JD, Osborne CK, Neidhardt JA, et al. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Investigational New Drugs 3: 149–152, 1985

    Article  PubMed  CAS  Google Scholar 

  • Creagan ET, Green SJ, Ahmann DL, et al. A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. Journal of Clinical Oncology 2: 1260–1265, 1984

    PubMed  CAS  Google Scholar 

  • Creech RH, Catalano RB, Hopson RC. A comparison of standard dose adriamycin and low dose adriamycin as primary chemotherapy for metastatic breast cancer. Proceedings of the American Association of Cancer Research 566: 142, 1980

    Google Scholar 

  • Cummings FJ, Gelman R, Horton J. Comparison of CAF versus CMFP in metastatic breast cancer. Analysis of prognostic factors. Journal of Clinical Oncology 3: 932–940, 1985

    CAS  Google Scholar 

  • Currie VE, Camacho F, Wittel R, et al. Phase II evaluation of vindesine in patients with advanced breast cancer. Cancer Treatment Reports 64: 693–695, 1980

    PubMed  CAS  Google Scholar 

  • s SR, Graham H, A’Hern RP, et al. A prospective randomized trial comparing low and high dose epirubicin given as either bolus injection or prolonged infusion for advanced breast cancer, p. 13. Abstract. Proceedings of the 3rd Scandinavian Breast Cancer Symposium, Orenäs, 1988

  • ertsen B, Pfeiffer P, Pedersen D, et al. Decreasing efficacy when reducing duration of chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil from 18 months to 6 months in the treatment of advanced breast cancer. European Journal of Cancer, in press, 1992 Fourth EORTC Breast Cancer Working Conference, London, June, 1987

  • French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. Journal of Clinical Oncology 4: 679–688, 1988

    Google Scholar 

  • French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. Journal of Clinical Oncology 9: 305–312, 1991

    Google Scholar 

  • Gallagher CJ, Cairnduff F, Smith IE. High dose vslow dose medroxyprogesterone acetate: a randomised trial in advanced breast cancer. European Journal of Cancer and Clinical Oncology 23: 1895–1900, 1987

    Article  CAS  Google Scholar 

  • /ohn P. A comparative randomized study of mitoxantrone and doxorubicin combination therapy in advanced breast cancer. Abstract. Second Nordic Novantrone Symposium, Oslo, 1988

  • Henderson IC. Chemotherapy for advanced disease. In Harris JR, et al. (Eds) Breast diseases, pp. 428–479, Lippincott, Philadelphia, 1987

    Google Scholar 

  • Henderson IC, Allegra JC, Woodstock T, et al. Randomized, clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. Journal of Clinical Oncology 7: 560–571, 1989

    PubMed  CAS  Google Scholar 

  • Henderson IC, Canellos GP. Cancer of the breast: the past decade. New England Journal of Medicine 302: 17–30, 1980a

    Article  PubMed  CAS  Google Scholar 

  • Henderson IC, Canellos GP. Cancer of the breast: the past decade. New England Journal of Medicine 302: 78–90, 1980b

    Article  PubMed  CAS  Google Scholar 

  • Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. Journal of Clinical Oncology 6: 1501–1515, 1988

    PubMed  CAS  Google Scholar 

  • Hoogstraten B, George SL, Samal B, et al. Combination chemotherapy and adriamycin in patients with advanced breast cancer. A South West Oncology Group Study. Cancer 38: 13–20, 1976

    CAS  Google Scholar 

  • Hortobagyi GN. Mitomycin C in breast cancer. Seminars in Oncology 12: 65–70, 1985

    PubMed  CAS  Google Scholar 

  • Hortobàgyi G, Bodey GP, Buzdar AU, et al. Evaluation of highdose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. Journal of Clinical Oncology 5: 554–564, 1987

    Google Scholar 

  • Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. Journal of Clinical Oncology 2: 1281–1288, 1984

    PubMed  CAS  Google Scholar 

  • Illiger HJ, ffier H, Carterier H, et al. Aminoglutethimide (AG) in advanced breast cancer (BC) — low dose vsstandard dose. Abstract. Journal of Cancer Research and Clinical Oncology 111 (Suppl.): 69, 1986

    Article  Google Scholar 

  • Ingle JN, Krook JE, Green SJ, et al. Randomised trial of bilateral oophorectomy vstamoxifen in premenopausal women with metastatic breast cancer. Journal of Clinical. Oncology 4: 178–185, 1986

    PubMed  CAS  Google Scholar 

  • Ingle JN, Mailliard JA, Schaid DJ, et al. Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. American Journal of Clinical Oncology 12: 474–480, 1989

    Article  PubMed  CAS  Google Scholar 

  • Italian Multicenter Breast Study with Epirubicin. Phase III ran- domized study of fluorouracil, epirubicin and cyclophosphamide vsfluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer. An Italian multicentre trial. Journal of Clinical Oncology 6: 976–982, 1988

    Google Scholar 

  • Jodrell DI, Smith IE, Mansi JL, et al. A randomized comparative trial of mitozantrone, methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate, 5-FU (CMF) in the treat- ment of advanced breast cancer. British Journal of Cancer 63: 794–798, 1991

    Article  PubMed  CAS  Google Scholar 

  • Kaufmann M, Jonat W, Kleeberg U, et al. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer: The German Zoladex Trial Group. Journal of Clinical Oncology 7: 1113–1119, 1989

    PubMed  CAS  Google Scholar 

  • Kim U, Depowski M. Progression from hormone dependence to autonomy in mammary tumours as an in vivomanifestation of sequential clonal selection. Cancer Research 35: 2068–2077, 1975

    PubMed  CAS  Google Scholar 

  • Kolaric K, Roth A, Vuhas D, et al. CAP (cyclophosphamide, adri- amycin, platinum) vsCMFVP (cyclophosphamide, methotrex- ate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. Cancer Chemotherapy and Pharmacology 13: 142–144, 1984

    CAS  Google Scholar 

  • Konig J, Halmer P, Franks CR, et al. Cardiozane-ICRF-187. To- wards anticancer drug specificity through selective toxicity re- duction. Cancer Treatment Reviews 18: 1–19, 1991

    Google Scholar 

  • Krook JE, Loprinzi CL, Schaid DJ, et al. Evaluation of the con- tinuous infusion of etoposide plus cisplatin in metastatic breast cancer. Cancer 65: 418–421, 1990

    Article  PubMed  CAS  Google Scholar 

  • nnsland S. Alternating sequences of tamoxifen and medroxy- progesterone acetate in postmenopausal women with ad- vanced breast cancer. Abstract. Proceedings of the Symposium on MPA in Malignant Tumors, Copenhagen, 9 September, 1986

  • Lemkin SR, Dollinger MR. Combination vssingle drug therapy in advanced breast cancer. Proceedings of the American As- sociation of Cancer Research 14: 37, 1973

    Google Scholar 

  • Lønning PE, Kvinnsland S. Mechanisms of action of aminoglu- tethimide as endocrine therapy of breast cancer. Drugs 35: 685–710, 1988

    Article  PubMed  Google Scholar 

  • riac L, Durrand M, Chauwergne J, et al. Randomised trial comparing alternating sequences of tamoxifen and medroxy- progesterone acetate with successive applications in metastatic breast cancer. Abstract 101. Proceedings of the International Symposium on Hormonal Manipulation of Cancer, Rotterdam, 4–6 June, 1986

  • Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treatment Reviews 16: 83–93, 1989

    Article  PubMed  CAS  Google Scholar 

  • Mouridsen HT. New cytotoxic drugs in treatment of breast cancer. Acta Oncologica 29: 343–347, 1990

    Article  PubMed  CAS  Google Scholar 

  • Mouridsen HT, Alphtan C, Bastholt L, et al. Current status of epirubicin (farmorubicin) in the treatment of solid tumors. Acta Oncologica 29: 257–285, 1990

    Article  PubMed  CAS  Google Scholar 

  • Mouridsen HT, Palshof T, Brahm, Rahbek I. Evaluation of single drug versus multiple drug chemotherapy in the treatment of advanced breast cancer. Cancer Treatment Reports 61: 47–50, 1977

    PubMed  CAS  Google Scholar 

  • Mouridsen HT, Palshof T, Patterson J, et al. Tamoxifen in ad- vanced breast cancer. Cancer Treatment Reviews 5: 131–141, 1978

    Article  PubMed  CAS  Google Scholar 

  • Muss HB, Case LD, Capizzi RL. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. Journal of Clinical Oncology 8: 1797–1805, 1990

    PubMed  CAS  Google Scholar 

  • Muss HB, White DR, Richards F, et al. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial. Cancer 42: 2141–2148, 1978

    CAS  Google Scholar 

  • Neidhardt JA, Gochnour D, Roach R, et al. A comparison of mitoxantrone and doxorubicin in breast cancer. Journal of Clinical Oncology 4: 672–677, 1986

    Google Scholar 

  • Nielsen D, Dombernowsky P, Skovgaard T, et al. Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study. Annals of Oncology 1: 275–280, 1990

    CAS  Google Scholar 

  • Noble R. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Research 37: 82–94, 1977

    PubMed  CAS  Google Scholar 

  • O’Bryan RM, Baker LH, Gottlieb JE, et al. Dose response eval- uation of adriamycin in human neoplasia. Cancer 39: 1340–1348, 1977

    Google Scholar 

  • Patterson JS.’Nolvadex’ (tamoxifen) as an anticancer agent in humans. In herland RL & Jordan VC (Eds) Non-steroidal antiestrogens: molecular pharmacology and antitumor activity, pp. 453–471, Sydney, New York, London, 1981

  • Pérez DJ, Harvey VJ, Robinson BA, et al. A randomized comparison of single-agent doxorubicin and epirubicin as first line cytotoxic therapy in advanced breast cancer. Journal of Clinical Oncology 9: 2148–2152, 1991

    PubMed  Google Scholar 

  • Periti P, Robustelli Delia Cuna G, Pannuti F, et al. Randomized study of 5-fluorouracil, epirubicin and cyclophosphamide vsfluorouracil, mitoxantrone and cyclophosphamide in advanced breast cancer: preliminary data. Abstract 57. Third 1ST International Symposium. Biology and Therapy of Breast Can- cer, Genoa, Italy, 1989

  • Pouillart P, Jouve M, Pallangie T, et al. Disseminated breast can- cer: sequential administration of tamoxifen and medroxypro- gesterone acetate. Results of a controlled trial. In Robustelli Delia Cuna, et al. (Eds) Role of medroxyprogesterone acetate in endocrine-related tumours, pp. 141–155, Raven, New York, 1984

    Google Scholar 

  • Powles TJ, Jones AL, Judson IR, et al. A randomized trial comparing combination chemotherapy using mitomycin C, mitoxantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Brit- ish Journal of Cancer 64: 406–410, 1991

    Article  CAS  Google Scholar 

  • Robustelli Delia Cuna G, Marini G, Baroni M, Gallotti P. Mul- ticenter randomized study of fluorouracil, cyclophosphamide plus epirubicin (FEC) or novantrone (FNC) in metastatic breast cancer. Abstract B 3.165.33. 15th International Cancer Con- gress, Hamburg, 1990

  • Rose C, Mouridsen HT. Combined cytotoxic and endocrine therapy in breast cancer. In Bresciani F, et al. (Eds) Progress in cancer research and treatment, Vol. 31, pp. 269–286, Raven Press, New York, 1984

    Google Scholar 

  • Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. Acta Oncologica 27: 721–728, 1988

    Article  PubMed  CAS  Google Scholar 

  • Rose C, Mouridsen HT, Bruning PF, et al. A randomised phase II study in postmenopausal patients with advanced breast can- cer comparing different doses of AG with and without the ad- dition of hydrocortisone (trial 10861). Abstract 1.13. Proceed- ings of the 4th EORTC Breast Cancer Working Conference, London, 1987a

  • Rose C, Mouridsen HT, Engelsman E, et al. Oral medroxypro- gesterone acetate treatment of postmenopausal patients with advanced breast cancer: an evaluation of the dose-response re- lationship at two dose levels: a phase III trial (trial 10802). Abstract FI 14. Proceedings of the 4th EORTC Breast Cancer Working Conference, London, 30 June-3 July, 1987b

  • Rubens RD, Knight RK, Hayward JL. Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. British Journal of Cancer 32: 730–736, 1975

    Article  PubMed  CAS  Google Scholar 

  • Santen RJ. Aromatase inhibitors: I. In Powles TJ & Smith IE (Eds) Medical management of breast cancer, pp. 61–79, Martin Dunitz, United Kingdom, 1991

    Google Scholar 

  • Sedlacek SM. An overview of megestrol acetate for the treatment of advanced breast cancer. Seminars in Oncology 15 (Suppl. 1): 3–13, 1988

    PubMed  CAS  Google Scholar 

  • Sluyser M, van Nier R. Estrogen receptor content and hormone responsive growth of mouse mammary tumors. Cancer Research 34: 3253–3257, 1974

    PubMed  CAS  Google Scholar 

  • Smalley RV, Carpenter J, Bartalucci A, et al. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A Southeastern Cancer Study Group Project. Cancer 40: 625–632, 1977

    Article  PubMed  CAS  Google Scholar 

  • Smalley RV, Murphy S, Huguley CM, et al. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Research 36: 3911–3916, 1976

    PubMed  CAS  Google Scholar 

  • Smith IE, Powles TJ. Chemotherapy: general principles. In Powles TJ & Smith IE (Eds) Medical management of breast cancer, pp. 125–137, Martin Dunitz, London, 1991

    Google Scholar 

  • Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. New England Journal of Medicine 319: 745–752, 1988

    Article  PubMed  CAS  Google Scholar 

  • Stewart DJ, Maroun JA, Hirte W, et al. A randomized compar- ison of cyclophosphamide-mitoxantrone-5-fluorouracil v cy- clophosphamide-doxorubicin-5-fluorouracil in advanced breast cancer. Seminars in Oncology 11 (Suppl. 1): 23–27, 1984

    PubMed  CAS  Google Scholar 

  • Stuart-Harris RC, Smith IE. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treatment Reviews 11: 189–204, 1984

    Article  PubMed  CAS  Google Scholar 

  • Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. Journal of Clinical Oncology 6: 1377–1387, 1988

    PubMed  CAS  Google Scholar 

  • Taylor SG, Gelman RS, Falkson G, et al. Combination chemo- therapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Annals of Internal Medicine 104: 455–461, 1986

    PubMed  Google Scholar 

  • Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M, et al. A comparison of intermittent vscontinuous and of adriamycin vsmethotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B Study. Amer- ican Journal of Clinical Oncology 7: 231–239, 1984

    CAS  Google Scholar 

  • Yap HY, Blumenschein GR, Hortobagyi GN, et al. A random- ized comparative study of vinblastine, vindesine and vincris- tine in patients with refractory breast cancer. Proceedings of the American Society of Clinical Oncologists 22: 441, 1981

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology 5074, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark

    H. T. Mouridsen

Authors
  1. H. T. Mouridsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mouridsen, H.T. Systemic Therapy of Advanced Breast Cancer. Drugs 44 (Suppl 4), 17–28 (1992). https://doi.org/10.2165/00003495-199200444-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199200444-00003

Keywords

Search

Navigation